David Rubin is a Managing Director and founding partner of GHI Fund, a healthcare investment firm focused on digital health and precision medicine in oncology, since its inception in 2010. With over 30 years of experience in the healthcare industry, he previously led the portfolio management group at Merck Research Labs. David joined Merck from Cognia Corporation, a venture-backed international healthcare R&D software company, where he was CEO. Previously, David was a management consultant at The Wilkerson Group/IBM Global Services. David is also a board member of several healthcare and digital health companies. Dr. Rubin holds a Ph.D. in Molecular Biology from Temple University and a B.A. in Biology from SUNY Binghamton. He completed post-doctoral fellowships at Harvard Medical School and received post-graduate business training at Harvard University.
